Back to mobile site

Valeant Pharma (VRX) Reports Q1 EPS of $1.30; Boosts FY13 EPS Outlook

May 2, 2013 6:28 AM EDT Send to a Friend
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $1.30, versus $0.91 reported ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login